Zoetis (ZTS) is having a Dividend Yield of 0.76% with the Annual cash Dividend per share of $0.38. The last quarter cash dividend per share pay out was $0.1. Zoetis has a 5 year average dividend yield of 0.73% and the stock has a Indicated annual dividend of $0.42. Zoetis (ZTS) has the most recent dividend payout ratio of 0.2 with a 5-year average payout ratio of 0.15. Companys change in pay out ratio when compared to the last 5 years average pay out ratio has been 0.04. The 5 year historical dividend growth of Zoetis (ZTS) is at the rate of 30.24% while the R-Squared dividend growth is 0.47. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
Zoetis Inc. (NYSE:ZTS) witnessed a decline in the market cap on Thursday as its shares dropped 4.3% or 2.37 points. After the session commenced at $54.69, the stock reached the higher end at $54.88 while it hit a low of $52. With the volume soaring to 12,881,819 shares, the last trade was called at $52.78. The company has a 52-week high of $56.5035. The company has a market cap of $26,064 million and there are 493,832,540 shares in outstanding. The 52-week low of the share price is $39.35. Zoetis Inc. has lost 5.68% in the last five trading days and dropped 0.98% in the last 4 weeks. Zoetis Inc. is up 7.6% in the last 3-month period. Year-to-Date the stock performance stands at -1.21%.
Currently the company Insiders own 0.05% of Zoetis Inc. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -30.71% . Institutional Investors own 94.54% of Zoetis Inc. shares. During last six month period, the net percent change held by insiders has seen a change of -36.49%. Company has reported several Insider transactions to the SEC, on Nov 23, 2016, Kristin C Peck (Executive Vice President) sold 10,092 shares at 49.55 per share price.On Nov 9, 2016, Roxanne Lagano (Executive Vice President) sold 9,797 shares at 50.43 per share price.On Sep 6, 2016, Michael B Mccallister (director) purchased 2,000 shares at 51.34 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Zoetis Inc was Initiated by Deutsche Bank on Dec 20, 2016 to Buy, Price Target of the shares are set at $62.Zoetis Inc was Resumed by Piper Jaffray to Overweight on Dec 15, 2016.
Zoetis Inc Last issued its quarterly earnings results on Feb 16, 2017. The company reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $0.46. The company had revenue of $1277.00 million for the quarter, compared to analysts expectations of $1274.22 million. The companys revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.
Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.